E to Week488 Journal of International Health-related Investigation 44(three)Figure two. Patient disposition inside a Norwegian trial comparing the efficacy and safety of celecoxib 200 and 400 mg after everyday (qd) and diclofenac 50 mg 3 times day-to-day (tid) in remedy of ankylosing spondylitis.Walker et al.Figure three. Adjust from baseline in Worldwide Pain Intensity at Week 12 in Norwegian sufferers with ankylosing spondylitis treated with celecoxib 200 or 400 mg everyday (qd) or diclofenac 50 mg three times each day (tid): intention-to-treat population. LS imply, least squares mean.Table 1. Alterations from baseline in secondary efficacy endpoints at Week 12 in Norwegian individuals with ankylosing spondylitis stratified as outlined by therapy group (celecoxib 200 or 400 mg day-to-day [qd] or diclofenac 50 mg three occasions day-to-day [tid]): intention-to-treat population. Celecoxib Parameter Nocturnal pain, n Baseline Week 12 LS mean alter from baselinea Difference in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c BASFI, n Baseline Week 12 LS imply alter from baselinea Difference in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c BASDAI, n Baseline Week 12 LS imply transform from baselinea 200 mg group 107 61.DKK-3 Protein Gene ID three 24.two 35.9 26.three 5.9 two.5 two.1 (.three, 9.five) 7.two (.4, 14.7) 107 48.1 21.eight 34.0 21.two four.9 1.8 three.two (.1, 8.six) three.3 (.two, 8.7) 107 58.four 20.7 40.six 21.0 17.5 1.9 400 mg group 108 57.9 23.3 27.6 23.four 3.1 2.5 .1 (2.5, two.3) 108 45.five 22.1 29.four 22.7 eight.two 1.eight .04 (.4, five.3) 107 52.eight 19.3 33. 21.6 0.eight 1.9 Diclofenac group 115 62.0 21.7 34.four 25.7 8.0 2.4 113 48.3 20.1 30.eight 20.0 8.1 1.7 114 56.two 18.eight 37.five 21.3 9.5 1.(continued)Table 1. Continued.Journal of International Healthcare Investigation 44(three)Celecoxib Parameter Difference in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c Physician’s Worldwide Assessment of Disease Severity, n Baseline Week 12 LS imply adjust from baselinea Difference in LS mean (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c Patient’s International Assessment of Illness Severity, n Baseline Week 12 LS imply alter from baselinea Difference in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c ASAS 20 responders, n ( )d Responders at Week 12 200 mg group 2.0 (.7, 7.6) 3.three (.five, 9.1) 107 58.three 16.six 36.six 18.7 1.1 two.0 1.eight (.0, 7.five) 2.five (.4, 8.three) 105 65.9 19.six 43.LIF, Human 4 24.PMID:23773119 7 3.0 two.7 three.5 (.four, 11.four) 5.0 (.0, 13.0) 107 55 (51.four) 400 mg group .3 (.0, 4.3) 108 55.two 17.0 33.1 20.0 three.five 1.9 .7 (.five, 5.1) 107 62.six 21.3 37.two 25.four 8.1 two.7 .5 (.4, six.four) 108 65 (60.2) Diclofenac group 114 59.0 16.three 35.6 20.7 two.9 1.9 112 67.five 18.0 40.7 26.7 six.5 two.6 115 66 (57.four)Data presented as: n or n ( ) individuals; 95 CI; imply SD (baseline and Week 12 information); imply SEM (LS imply adjust from baseline). a Derived from evaluation of covariance with baseline as a covariate, and treatment and centre as things. b Calculated as difference involving treatment groups in change from baseline. A damaging distinction indicates a numerical superiority of celecoxib more than diclofenac. c Tukey ramer numerous comparison process applied to generate self-assurance interval and P-value. d Pairwise comparisons in between therapy groups at Week 12 have been produced using Fisher’s exact test. No substantial between-group variations (200 mg qd celecoxib vs diclofenac, 400 mg celecoxib vs diclofenac, or 200 mg celecoxib vs 400 mg celecoxib; P ! 0.05). BASFI, Bath Ankylosing Spondylitis Functional Index; BAS.